Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Outline of Final Research Achievements |
A somatic mutation (V617F) in tyrosine kinase JAK2 was found in the majority of myeloproliferative neoplasm (MPN) patients. It has been shown that the JAK2 V617F mutant was constitutively active and induced the cytokine-independent cell proliferation and tumorigenesis, suggesting that it behaves as a potent oncogene product. However, the molecular mechanism how JAK2 V617F mutant induces cellular transformation has not been elucidated. To clarify the molecular mechanism of JAK2 V617F mutant-induced transformation, it is necessary to analyze the states of all signal molecules at the downstream of JAK2 V617F mutant at the same time. Therefore, we performed quantitative phosphoproteome analysis to identify the phosphorylated proteins at downstream of JAK2 V617F mutant and analyze the roles of these molecules.
|